201 related articles for article (PubMed ID: 27378673)
1. High-affinity von Willebrand factor binding does not affect the anatomical or hepatocellular distribution of factor VIII in rats.
Øie CI; Roepstorff K; Behrens C; Bøggild Kristensen J; Karpf DM; Bolt G; Gudme CN; Kjalke M; Smedsrød B; Appa RS
J Thromb Haemost; 2016 Sep; 14(9):1803-13. PubMed ID: 27378673
[TBL] [Abstract][Full Text] [Related]
2. FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.
van der Flier A; Liu Z; Tan S; Chen K; Drager D; Liu T; Patarroyo-White S; Jiang H; Light DR
PLoS One; 2015; 10(4):e0124930. PubMed ID: 25905473
[TBL] [Abstract][Full Text] [Related]
3. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
Vargas Christensen I; Loftager M; Rode F; Mørck Nielsen H; Kreilgaard M; Larsen MS
J Thromb Haemost; 2019 Jun; 17(6):964-974. PubMed ID: 30924607
[TBL] [Abstract][Full Text] [Related]
4. The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.
Swystun LL; Notley C; Georgescu I; Lai JD; Nesbitt K; James PD; Lillicrap D
J Thromb Haemost; 2019 Apr; 17(4):681-694. PubMed ID: 30740857
[TBL] [Abstract][Full Text] [Related]
5. Interaction between VWF and FVIII in treating VWD.
Miesbach W; Berntorp E
Eur J Haematol; 2015 Nov; 95(5):449-54. PubMed ID: 25605439
[TBL] [Abstract][Full Text] [Related]
6. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications.
Casonato A; Pontara E; Zerbinati P; Zucchetto A; Girolami A
Am J Clin Pathol; 1998 Mar; 109(3):347-52. PubMed ID: 9495210
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
Elsheikh E; Lavin M; Heck LA; Larkin N; Mullaney B; Doherty D; Kennedy M; Keenan C; Guest T; O'Mahony B; Fazavana J; Fallon PG; Preston RJS; Gormley J; Ryan K; O'Connell NM; Singleton E; Byrne M; McGowan M; Roche S; Doyle M; Crowley MP; O'Shea SI; Reipert BM; Johnsen JM; Pipe SW; Di Paola J; Turecek PL; O'Donnell JS;
J Thromb Haemost; 2023 May; 21(5):1123-1134. PubMed ID: 36775768
[TBL] [Abstract][Full Text] [Related]
8. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
Cattaneo M; Simoni L; Gringeri A; Mannucci PM
Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
[TBL] [Abstract][Full Text] [Related]
9. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
11. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.
Nishino M; Nishino S; Sugimoto M; Shibata M; Tsuji S; Yoshioka A
Int J Hematol; 1996 Aug; 64(2):127-34. PubMed ID: 8854570
[TBL] [Abstract][Full Text] [Related]
12. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
Jacquemin M
Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
Castaman G; Federici AB; Bernardi M; Moroni B; Bertoncello K; Rodeghiero F
J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
[TBL] [Abstract][Full Text] [Related]
14. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
Karlman M; Holmström M; Wiman B
Thromb Res; 2011 Jan; 127(1):47-50. PubMed ID: 21094987
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models.
Denis CV; Kwack K; Saffaripour S; Maganti S; André P; Schaub RG; Wagner DD
Blood; 2001 Jan; 97(2):465-72. PubMed ID: 11154224
[TBL] [Abstract][Full Text] [Related]
16. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
López-Fernández MF; Blanco-López MJ; Castiñeira MP; Batlle J
Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
[TBL] [Abstract][Full Text] [Related]
17. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo.
Cao W; Trask AR; Bignotti AI; George LA; Doshi BS; Sabatino DE; Yada N; Zheng L; Camire RM; Zheng XL
J Thromb Haemost; 2023 Dec; 21(12):3477-3489. PubMed ID: 37726033
[TBL] [Abstract][Full Text] [Related]
18. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
Seth Chhabra E; Liu T; Kulman J; Patarroyo-White S; Yang B; Lu Q; Drager D; Moore N; Liu J; Holthaus AM; Sommer JM; Ismail A; Rabinovich D; Liu Z; van der Flier A; Goodman A; Furcht C; Tie M; Carlage T; Mauldin R; Dobrowsky TM; Liu Z; Mercury O; Zhu L; Mei B; Schellenberger V; Jiang H; Pierce GF; Salas J; Peters R
Blood; 2020 Apr; 135(17):1484-1496. PubMed ID: 32078672
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
[TBL] [Abstract][Full Text] [Related]
20. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
Kroner PA; Foster PA; Fahs SA; Montgomery RR
Blood; 1996 Feb; 87(3):1013-21. PubMed ID: 8562925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
